LINC00504 Promotes the Malignant Biological Behavior of Breast Cancer Cells by Upregulating HMGB3 via Decoying MicroRNA-876-3p.
ceRNA
high mobility group box 3
long intergenic non-protein coding RNA 504
therapeutic target
Journal
Cancer management and research
ISSN: 1179-1322
Titre abrégé: Cancer Manag Res
Pays: New Zealand
ID NLM: 101512700
Informations de publication
Date de publication:
2021
2021
Historique:
received:
09
08
2020
accepted:
26
01
2021
entrez:
3
3
2021
pubmed:
4
3
2021
medline:
4
3
2021
Statut:
epublish
Résumé
Long intergenic non-protein coding RNA 504 (LINC00504) is a long non-coding RNA that has an important regulatory role in a variety of human cancers. In this study, LINC00504 expression in breast cancer tissues and cell lines was detected. Studies were also conducted to determine the impact of LINC00504 on the tumor behavior of breast cancer cells. The potential mechanisms underlying the oncogenic role of LINC00504 in breast cancer cells were elucidated in detail. Expression of LINC00504 in breast cancer was analyzed by quantitative real-time polymerase chain reaction. The effects of LINC00504 on proliferation, apoptosis, in vitro migration and invasion, and in vivo tumor growth were elucidated using Cell Counting Kit-8 assay, flow cytometry, Transwell assays, and tumor xenograft models, respectively. Bioinformatics analyses in conjunction with RNA immunoprecipitation, luciferase reporter assays, and rescue experiments were conducted to investigate the underlying molecular mechanisms. LINC00504 was upregulated in breast cancer tissues and cell lines. Knocking down LINC00504 suppressed breast cancer cell proliferation, migration, and invasion and facilitated apoptosis in vitro. In addition, tumor growth in vivo was significantly inhibited by LINC00504 depletion. Regarding the underlying mechanism, LIN00504 could function as a competing endogenous RNA in breast cancer by sponging microRNA-876-3p (miR-876-3p), resulting in the upregulation of high mobility group box 3 (HMGB3). Rescue experiments further revealed that miR-876-3p downregulation or HMGB3 upregulation effectively reversed the inhibitory effects of LIN00504 deficiency on breast cancer cells. The LIN00504-miR-876-3p-HMGB3 axis shows carcinogenic effects in modulating the biological behavior of breast cancer cells. This pathway may represent an effective target for CRC diagnosis and anticancer therapy.
Identifiants
pubmed: 33654429
doi: 10.2147/CMAR.S276290
pii: 276290
pmc: PMC7910115
doi:
Types de publication
Journal Article
Retracted Publication
Langues
eng
Pagination
1803-1815Commentaires et corrections
Type : ExpressionOfConcernIn
Type : RetractionIn
Informations de copyright
© 2021 Yu et al.
Déclaration de conflit d'intérêts
The authors declare that they have no competing interests.
Références
Asian Pac J Cancer Prev. 2016;17(4):1595-608
pubmed: 27221827
Cancers (Basel). 2020 May 31;12(6):
pubmed: 32486413
Int J Mol Sci. 2019 Nov 08;20(22):
pubmed: 31717266
Anticancer Agents Med Chem. 2017;17(2):152-163
pubmed: 27137076
World J Gastroenterol. 2020 Jun 28;26(24):3401-3412
pubmed: 32655264
Cell Mol Biol (Noisy-le-grand). 2020 Jun 05;66(3):72-78
pubmed: 32538750
Int J Mol Sci. 2019 Nov 16;20(22):
pubmed: 31744051
Adv Exp Med Biol. 2017;1008:199-222
pubmed: 28815541
Cancer Res. 2017 Aug 1;77(15):3965-3981
pubmed: 28701486
Onco Targets Ther. 2020 May 18;13:4271-4282
pubmed: 32547061
Cell. 2009 Feb 20;136(4):629-41
pubmed: 19239885
Cancer Manag Res. 2019 May 31;11:5075-5089
pubmed: 31213919
Am J Transl Res. 2019 Aug 15;11(8):4957-4966
pubmed: 31497212
Int J Mol Sci. 2020 Mar 03;21(5):
pubmed: 32138313
Cancers (Basel). 2020 May 09;12(5):
pubmed: 32397382
Semin Cancer Biol. 2020 Jun 30;:
pubmed: 32619506
PLoS One. 2013 Oct 02;8(10):e76402
pubmed: 24098490
J Cell Biochem. 2019 Sep;120(9):14725-14734
pubmed: 30998289
J BUON. 2020 Mar-Apr;25(2):621-626
pubmed: 32521844
Cell. 2009 Feb 20;136(4):669-87
pubmed: 19239888
Oncol Rev. 2017 May 16;11(1):323
pubmed: 28584571
Eur Rev Med Pharmacol Sci. 2020 Jan;24(2):699-703
pubmed: 32016971
Onco Targets Ther. 2020 Mar 23;13:2411-2419
pubmed: 32273714
Mol Cell Pharmacol. 2011;3(3):83-92
pubmed: 22468167
Nature. 2019 May;569(7757):560-564
pubmed: 31118521
Noncoding RNA. 2020 Jun 30;6(3):
pubmed: 32629922
Am J Cancer Res. 2018 Apr 01;8(4):636-649
pubmed: 29736309
CA Cancer J Clin. 2019 Jan;69(1):7-34
pubmed: 30620402
Tumour Biol. 2014 Nov;35(11):11081-9
pubmed: 25095979
JCO Clin Cancer Inform. 2020 Jun;4:500-513
pubmed: 32479187
Genomics Proteomics Bioinformatics. 2016 Apr;14(2):73-80
pubmed: 27163185
Int J Biol Sci. 2017 Nov 1;13(11):1387-1397
pubmed: 29209143
Mol Cell Biochem. 2020 Jan;464(1-2):39-50
pubmed: 31691157
Int J Biochem Cell Biol. 2019 Feb;107:69-76
pubmed: 30543931
J Breast Cancer. 2020 Jan 16;23(2):129-140
pubmed: 32395373